The Oncology Institute, Inc. (NASDAQ:TOI) Short Interest Up 25.2% in August

The Oncology Institute, Inc. (NASDAQ:TOI) was the recipient of a large increase in short interest during the month of August. As of August 31st, there was short interest totalling 301,700 shares, an increase of 25.2% from the August 15th total of 240,900 shares. Based on an average daily volume of 144,100 shares, the days-to-cover ratio is currently 2.1 days. Currently, 0.9% of the shares of the company are short sold.

Oncology Institute Price Performance

TOI stock traded down $0.01 during trading on Monday, reaching $0.32. 495 shares of the company were exchanged, compared to its average volume of 151,748. The stock’s 50 day moving average price is $0.43 and its 200 day moving average price is $0.81. The company has a market cap of $23.89 million, a P/E ratio of -0.41 and a beta of 0.61. The company has a debt-to-equity ratio of 3.08, a quick ratio of 2.99 and a current ratio of 3.31. Oncology Institute has a 52-week low of $0.27 and a 52-week high of $2.66.

Oncology Institute (NASDAQ:TOI) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.07). Oncology Institute had a negative net margin of 18.86% and a negative return on equity of 136.63%. The firm had revenue of $98.58 million for the quarter, compared to analysts’ expectations of $103.31 million. During the same period in the previous year, the company posted ($0.19) EPS. As a group, analysts predict that Oncology Institute will post -0.63 earnings per share for the current fiscal year.

Institutional Trading of Oncology Institute

Several institutional investors and hedge funds have recently bought and sold shares of TOI. Quattro Financial Advisors LLC acquired a new stake in Oncology Institute in the first quarter worth about $88,000. Nwam LLC acquired a new stake in shares of Oncology Institute during the 1st quarter valued at about $44,000. Kent Lake Capital LLC grew its position in Oncology Institute by 9.4% in the first quarter. Kent Lake Capital LLC now owns 1,186,713 shares of the company’s stock worth $1,875,000 after acquiring an additional 101,542 shares in the last quarter. FourWorld Capital Management LLC acquired a new position in Oncology Institute during the first quarter worth $396,000. Finally, Tiff Advisory Services LLC raised its stake in shares of Oncology Institute by 235.1% in the 2nd quarter. Tiff Advisory Services LLC now owns 1,418,685 shares of the company’s stock valued at $653,000 after acquiring an additional 995,280 shares in the last quarter. Institutional investors and hedge funds own 36.86% of the company’s stock.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.